Yaoming biological Co., Ltd. is authorized to use wuxibody (TM) to develop five double antibodies with us $450 million

December 11, 2018 / Meitong news agency / -- Wuxi biology, the world's leading open biopharmaceutical technology platform company, 2269 HK) announced today that it will further deepen strategic cooperation with Oxford biotherapeutics (obt), a British biotechnology company with multiple clinical stage product lines in the field of tumor immunity and antibody coupled drugs (ADC), and authorize it to use wuxibody with independent intellectual property rights Gamma Five new bispecific antibodies were developed on the bispecific antibody development platform Through this cooperation, obt will make full use of its advantages in drug discovery and development, and develop and commercialize a new generation of tumor antibody drugs with the help of its rich experience in the field of bispecific antibodies According to the strategic cooperation agreement, obt is authorized to use the patented wuxibody Gamma Technology platform, which can be used to promote the R & D and commercialization of five bispecific antibodies; pharmaceutics will obtain the platform's authorized down payment, product approval registration and commercialization milestone payment, with a total amount of up to $450 million, as well as the sales commission calculated according to the global sales volume after the product is launched "Our strategic cooperation in the field of tumor immunity with Yaoming biology is essential for the company's development, based on wuxibody Gamma Technical platform and PD-L1 technical cooperation will help us to deepen and broaden the company's first-class tumor immune research and development pipeline " Dr Christian Rohlff, chief executive officer of obt, said, "we are very happy to use wuxibody Gamma Technology, the combination of the second generation tumor immune innovative drugs of obt company with mainstream immune checkpoint inhibitors, is expected to develop innovative drugs with wide indications in solid tumors and blood tumors, and bring new treatment plans for patients who cannot benefit from existing tumor immune products Using innovative dual anti platform wuxibody Gamma It can optimize the risk-benefit ratio of new drugs, reduce the cost of research and development, and optimize the potential commercial value of products This cooperation will enable the company's product development strategy to stand out in the field of tumor immunotherapy, develop key products that are expected to change the future landscape of tumor treatment, and help the obt achieve the goal of "curing cancer" "We are happy to use wuxibody Gamma The platform further deepens the strategic partnership with the obt company, which is the third strategic cooperation reached by the platform since its global debut in September this year " Dr Chen Zhisheng, CEO of YaoMing biology, said, "the company has independent intellectual property rights for the development platform of dual specificity antibody, wuxibody Gamma Widely recognized by partners, it fully demonstrates its strong strength, not only breaking through the limitations of similar technology platforms, but also significantly reducing the production cost of bispecific antibodies At present, the highest expression of bispecific antibody is 16g / L, and the purity and yield of protein a purified in one step are over 95% We will continue to invest in the development of the world's leading innovative technologies and realize the vision of accelerating and transforming the development and production process of biopharmaceuticals " About wuxibody Gamma WuXiBody Gamma It is a bispecific antibody technology platform with independent intellectual property rights, and is expected to become one of the best bispecific antibody platforms in the industry This platform has broken through the technical bottleneck of most bispecific antibody platforms, effectively overcome the challenges of low expression, high polymer and low purification yield in the development process of bispecific antibodies, and has the advantages of saving 6-18 months of R & D time for each project and significantly reducing the production cost of bispecific antibodies At present, the expression of bispecific antibody is up to 16g / L, and the purity and yield of purified protein A are over 95% Meanwhile, wuxibody Gamma The platform also has unique flexibility to build a variety of valence numbers (such as bivalent, trivalent or tetravalent bispecific antibodies) and structures to meet the biological characteristics of different projects About Oxford BioTherapeutics OBT is a clinical stage company that develops new tumor immunotherapy and antibody coupled drugs (ADC) for the unmet clinical needs in the field of cancer The company is headquartered in Oxford, UK and has a branch in San Jose, USA The tumor immunotherapy developed by obt has provided original insights for the synaptic theory of immune cells, and several new candidate drugs for cancer treatment have been identified Two leading clinical projects in the R & D pipeline of obt are men1112 (obt357) and men1309 (obt076) The former is a monoclonal antibody candidate drug targeting CD157 (expressed in AML cells and leukemic stem cells), which is currently in the phase I dose increasing trial stage, and is used to treat relapsed / refractory AML; the latter is a DM4 antibody coupled drug targeting CD205, which is used to treat metastatic triple negative breast cancer, bladder cancer and pancreatic cancer And non Hodgkin's lymphoma At present, men1309 (obt076) is also in phase I clinical dose increasing test in EU Obt's product pipeline and development capabilities have been proven through a number of strategic partnerships with global leaders in antibody development, including companies such as Seattle Genetics, Amgen, alere, biowa, medarex and menarini, the European pharmaceutical companies, all of which have provided abundant financial support for the clinical phase II concept validation test conducted by the two projects in the European Union At the same time, the company retains the commercial rights and interests of the products in the North American and Japanese markets In addition, bringer ingelham is also a partner of two preclinical projects of the company Obt has a strong management team and board focusing on the field of cancer, and they have rich experience in the development of tumor immunotherapy and antibody therapy For more information, please visit www.oxfordbiotherapeutics.com As a Hong Kong listed company, Yaoming bio (Stock Code: 2269 HK) is the world's leading open, integrated bio pharmaceutical capability and technology enabling platform The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2018, 187 comprehensive projects have been developed on the platform, including 98 in the preclinical research stage, 78 in the early clinical stage (phase I, phase II), 10 in the late clinical stage (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.